Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation

Denosumab is a first-line therapy for osteoporosis, yet the rebound increase in bone turnover markers, rapid bone loss, and elevated fracture risk following its discontinuation have become major challenges in clinical management. This review systematically summarizes the potential mechanisms underlying exacerbated bone...

Jiancheng Yang, Ming Yang, Yuhong Zeng · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.